Rhythm Pharmaceuticals (RYTM) EBIT: 2020-2025
Historic EBIT for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -$52.7 million.
- Rhythm Pharmaceuticals' EBIT fell 19.98% to -$52.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$186.2 million, marking a year-over-year increase of 29.87%. This contributed to the annual value of -$265.5 million for FY2024, which is 44.02% down from last year.
- Latest data reveals that Rhythm Pharmaceuticals reported EBIT of -$52.7 million as of Q3 2025, which was down 16.24% from -$45.3 million recorded in Q2 2025.
- Over the past 5 years, Rhythm Pharmaceuticals' EBIT peaked at -$34.4 million during Q1 2021, and registered a low of -$139.9 million during Q1 2024.
- Over the past 3 years, Rhythm Pharmaceuticals' median EBIT value was -$45.3 million (recorded in 2025), while the average stood at -$54.1 million.
- In the last 5 years, Rhythm Pharmaceuticals' EBIT tumbled by 166.29% in 2024 and then surged by 66.40% in 2025.
- Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' EBIT stood at -$51.0 million in 2021, then grew by 17.43% to -$42.1 million in 2022, then climbed by 1.99% to -$41.3 million in 2023, then increased by 0.02% to -$41.3 million in 2024, then fell by 19.98% to -$52.7 million in 2025.
- Its last three reported values are -$52.7 million in Q3 2025, -$45.3 million for Q2 2025, and -$47.0 million during Q1 2025.